Takeda's once-monthly anaemia treatment accepted for EMA review PMLiVE The drug, which was discovered by Affymax, is a potential new treatment for symptomatic anaemia associated with chronic kidney disease (CKD) in adult patients on dialysis. If approved, Takeda will market the product alone in the EU, while in the US, ... Takeda Announces Acceptance of European Marketing Authorisation Application ... Search in our News Channels Affymax to Receive $5 Million Milestone Payment for Acceptance of European ... |
